Cargando…

The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?

Detalles Bibliográficos
Autores principales:	Sgalla, Giacomo, Wijsenbeek, Marlies S., Richeldi, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838618/ https://www.ncbi.nlm.nih.gov/pubmed/35134312 http://dx.doi.org/10.1164/rccm.202201-0018ED

Ejemplares similares

Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis)
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
por: Wijsenbeek, Marlies S., et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis: pathogenesis and management
por: Sgalla, Giacomo, et al.
Publicado: (2018)

Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report
por: Cerri, Stefania, et al.
Publicado: (2016)

COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis: moving forward
por: Richeldi, Luca
Publicado: (2015)

Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don’t
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
por: Moor, Catharina C., et al.
Publicado: (2017)

Cough in idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2016)

Guidelines or guidance for better idiopathic pulmonary fibrosis management?
por: Behr, Jürgen
Publicado: (2016)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Reply to Huang and Wei, Kang et al., and Ehteshami-Afshar and Raj
por: Sgalla, Giacomo, et al.
Publicado: (2022)

GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosis
por: Gobbo, Francesca, et al.
Publicado: (2023)

Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region
por: Di Bidino, Rossella, et al.
Publicado: (2022)

The use of online visual analogue scales in idiopathic pulmonary fibrosis
por: Moor, Catharina C., et al.
Publicado: (2022)

The 2018 Diagnosis of Idiopathic Pulmonary Fibrosis Guidelines: Surgical Lung Biopsy for Radiological Pattern of Probable Usual Interstitial Pneumonia Is Not Mandatory
por: Raghu, Ganesh, et al.
Publicado: (2019)

Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment
por: Cottin, Vincent, et al.
Publicado: (2014)

Social Inequities and Cystic Fibrosis Outcomes: We Can Do Better
por: Oates, Gabriela R., et al.
Publicado: (2021)

Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis
por: Jones, Mark G., et al.
Publicado: (2016)

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
por: De Biasi, Sara, et al.
Publicado: (2015)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges
por: Spagnolo, Paolo, et al.
Publicado: (2012)

Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
por: Hadda, Vijay, et al.
Publicado: (2020)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
por: Richeldi, Luca, et al.
Publicado: (2023)

Can we improve operating room efficiency?
por: Divatia, JV, et al.
Publicado: (2015)

Integrated 'Omics in Idiopathic Pulmonary Fibrosis: Where Do We Go from Here?
por: Castaldi, Peter J.
Publicado: (2021)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis
por: Jouneau, Stéphane, et al.
Publicado: (2020)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials
por: Collard, Harold R, et al.
Publicado: (2013)

We can do much better than what we did
por: Lee, Sang-Hak
Publicado: (2020)

How can we better predict pulmonary blood clots in patients hospitalised for COVID-19?
por: Bertoletti, Laurent, et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2015)

State of the Art in Idiopathic Pulmonary Fibrosis
por: El Agha, Elie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0mcsjdsp0gu2ouqevmo1gu3olk